FDA approves Abbott's Volt PFA system for AFib treatment
The U.S. Food and Drug Administration (FDA) has approved Abbott Laboratories' Volt pulsed-field ablation (PFA) system. The technology is intended to treat patients with atrial fibrillation (AFib) and prevent related irregular heartbeats.
Abbott Laboratories has received FDA approval for its Volt pulsed-field ablation (PFA) system, marking a new option for treating atrial fibrillation (AFib). AFib is the most common type of irregular heartbeat and can lead to heart failure if left untreated.
The Volt PFA system utilizes pulsed electrical energy to target and ablate specific heart tissue responsible for irregular electrical signals. Unlike traditional thermal ablation methods, which use heat or cold, PFA is designed to selectively affect heart muscle tissue while sparing surrounding structures such as the phrenic nerve and esophagus. This selective approach aims to improve procedural safety.
Abbott states the system's design includes a unique basket-like electrode pattern around a small balloon. When inflated, the balloon directs the electrical pulses more precisely into the heart muscle, potentially increasing lesion depth and ensuring effective deactivation of abnormal electrical pathways. This design is intended to facilitate faster and more effective treatment of AFib.
"Pulsed-field ablation spares the phrenic nerve, which runs to the diaphragm and helps the patient breathe. It spares the esophagus. It has great potential to make these procedures even safer," said Dr. Christopher Piorkowski, Chief Medical Officer of Electrophysiology at Abbott. Abbott notes that some patients may experience benefits within days of the procedure, such as improved ability to perform daily activities.
The regulatory clearance for the Volt PFA system underscores Abbott's ongoing efforts in cardiovascular care and aims to provide physicians with advanced tools to manage AFib, potentially improving patient outcomes and quality of life.